Molecular Effects of Topical Calcipotriene on Morphea

Inclusion Criteria: * Subjects with clinically-diagnosed or biopsy proven plaque-type, guttate, linear, segmental, and generalized morphea that are receiving calcipotriene 0.005% ointment as part of their standard of care treatment will be included. * Subjects are allowed to have previously been on any therapy as long as they have been off systemic treatment, topical therapy or phototherapy for 4 weeks prior to baseline. * Age ≥ 18 years. * Ability to understand and the willingness to sign a written informed consent. Exclusion Criteria: * Subjects with the diagnosis of morphea profundus, eosinophilic fasciitis, and atrophoderma will be excluded. * Subjects who are receiving oral or topical immunosuppression therapy or phototherapy within 4 weeks prior to entering the study. * Subjects may not be receiving any investigational agents. * Subjects must not be pregnant or nursing. * Patients allergic to lidocaine or epinephrine or who have a history of impaired wound healing or for any reason are unable to undergo a skin biopsy.